An overview of EBMT 2017 by Prof. Mohamad Mohty
Why we need novel strategies for diffuse large B-cell lymphoma
Predicting resistance to therapy in CLL
Minimal residual disease (MRD) monitoring for multiple myeloma is here to stay
Precision medicine for MDS, what drugs for which patients?